Payment overview · 2025
General Payments
$337.94
14 reported records · 11 companies
Healthcare provider profile · identity verified
Samantha Anne Easterly, DO
Allopathic & Osteopathic Physicians|Family Medicine · COEUR D ALENE, ID · NPI 1003473380
Verified facts
What the public records show
CMS Open Payments records show Samantha Anne Easterly, DO received $337.94 in general payments during 2025 across 14 reported records.
ABBVIE INC. accounted for 24.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Armour Thyroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $82.56 | 24.4% | 3 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $36.85 | 10.9% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $35.79 | 10.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $31.57 | 9.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $30.93 | 9.2% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $29.66 | 8.8% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $20.92 | 6.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.91 | 5.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.57 | 5.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.55 | 4.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.63 | 4.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $337.94 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $82.56 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $58.44 | 2 | 2025 |
Source payment records
|
|||||
| Extended Holter Normalized: extended holter |
Device | Philips North America LLC | $36.85 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $35.79 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $31.57 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $30.93 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $29.66 | 1 | 2025 |
Source payment records
|
|||||
| AMS 700 Normalized: ams 700 |
Device | Boston Scientific Corporation | $20.92 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.57 | 1 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $16.55 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 282 | 58 |
| Atorvastatin Calcium | Atorvastatin Calcium | 250 | 83 |
| Losartan Potassium | Losartan Potassium | 176 | 50 |
| Lisinopril | Lisinopril | 157 | 47 |
| Gabapentin | Gabapentin | 156 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 140 | 73 |
| Trazodone Hcl | Trazodone Hcl | 139 | 38 |
| Omeprazole | Omeprazole | 126 | 48 |
| Amlodipine Besylate | Amlodipine Besylate | 125 | 36 |
| Simvastatin | Simvastatin | 109 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 106 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 102 | 33 |
| Sertraline Hcl | Sertraline Hcl | 91 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 89 | 31 |
| Alendronate Sodium | Alendronate Sodium | 86 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 85 | 22 |
| Famotidine | Famotidine | 85 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 73 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 70 | 36 |
| Diclofenac Sodium | Diclofenac Sodium | 69 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 62 | 23 |
| Methocarbamol | Methocarbamol | 59 | 13 |
| Metformin Hcl Er | Metformin Hcl | 58 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 20 |
| Metformin Hcl | Metformin Hcl | 53 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 52 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 51 | suppressed |
| Prednisone | Prednisone | 49 | 28 |
| Lovastatin | Lovastatin | 48 | 15 |
| Meloxicam | Meloxicam | 47 | 18 |
| Furosemide | Furosemide | 46 | 19 |
| Allopurinol | Allopurinol | 45 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | 13 |
| Montelukast Sodium | Montelukast Sodium | 45 | 15 |
| Liothyronine Sodium | Liothyronine Sodium | 43 | suppressed |
| Pregabalin | Pregabalin | 41 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 16 |
| Potassium Chloride | Potassium Chloride | 38 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 37 | 14 |
| Valacyclovir | Valacyclovir Hcl | 35 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 34 | suppressed |
| Carvedilol | Carvedilol | 33 | suppressed |
| Sucralfate | Sucralfate | 33 | 14 |
| Donepezil Hcl | Donepezil Hcl | 31 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 19 |
| Glipizide Er | Glipizide | 27 | suppressed |
| Ozempic | Semaglutide | 27 | suppressed |
| Atenolol | Atenolol | 26 | suppressed |
| Eliquis | Apixaban | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 26 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Ketoconazole | Ketoconazole | 22 | 14 |
| Nystatin | Nystatin | 22 | 15 |
| Celecoxib | Celecoxib | 21 | suppressed |
| Jardiance | Empagliflozin | 21 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 21 | 11 |
| Tramadol Hcl | Tramadol Hcl | 21 | suppressed |
| Ursodiol | Ursodiol | 21 | suppressed |
| Azithromycin | Azithromycin | 20 | 18 |
| Cephalexin | Cephalexin | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Alprazolam | Alprazolam | 19 | 11 |
| Ondansetron Odt | Ondansetron | 19 | 15 |
| Fluconazole | Fluconazole | 18 | 11 |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $337.94 · 14 records | ABBVIE INC. | AMS 700, Cologuard Collection Kit, DUPIXENT, Extended Holter, JARDIANCE, MOUNJARO, Ohtuvayre, QULIPTA, TEZSPIRE, TRELEGY ELLIPTA, UBRELVY | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error